The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Cassava Sciences, Inc(NASDAQ:SAVA)


Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-b...
Website: https://www.cassavasciences.com/
Founded: 1998
Full Time Employees: 9
CEO: Remi Barbier
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
Cassava Sciences Days Payable Outstanding ttm (DPO)
Cassava Sciences Days Receivable Outstanding ttm (DSO)
Cassava Sciences Op Cashflow Per Share ttm
Cassava Sciences Free Cashflow Per Share ttm
Cassava Sciences Cash Per Share ttm
Cassava Sciences P/S ratio ttm
Cassava Sciences (GAAP) P/E ratio ttm
Cassava Sciences P/B ratio ttm
No extra charts and metrics for this ticker.